Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Yellow Fever01:18

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on combination therapies against HBV in clinical investigations.

Antiviral research·2025
Same author

Recurrent Erythropoietic Protoporphyria Post Liver Transplant.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.

Hepatology (Baltimore, Md.)·2025
Same author

Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.

Hepatology communications·2025
Same author

Case-based Clinical Reasoning Competitions: A Novel Method to Teach and Assess Clinical Reasoning Skills Among Gastroenterologists.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology·2024
Same author

Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.

Hepatology (Baltimore, Md.)·2024
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Update on viral hepatitis: 2008.

Bulent Degertekin1, Anna S F Lok

  • 1Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA.

Current Opinion in Gastroenterology
|April 24, 2009
PubMed
Summary
This summary is machine-generated.

Recent advancements in viral hepatitis treatment show declining hepatitis A and B incidence. New antiviral therapies offer promise for chronic hepatitis B and C, with personalized treatment strategies improving outcomes.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Experiment Videos

Last Updated: Jun 23, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Viral hepatitis remains a significant global health concern.
  • Recent publications (Dec 2007-Nov 2008) highlight evolving treatment landscapes.

Purpose of the Study:

  • To provide a concise review of recent developments in viral hepatitis.
  • To summarize key findings in the treatment of hepatitis A, B, C, and E.

Main Methods:

  • Literature review of publications from December 2007 to November 2008.
  • Analysis of reported clinical outcomes and therapeutic advancements.

Main Results:

  • Significant decline in acute hepatitis A and B infections, particularly in children.
  • Approval of five oral antiviral agents for chronic hepatitis B.
  • Telbivudine shows potency but higher resistance rates than entecavir or tenofovir.
  • Combination therapies and individualized dosing of pegylated interferon and ribavirin show promise for hepatitis C.
  • Emerging evidence of chronic hepatitis E in transplant recipients.

Conclusions:

  • Multiple treatment options exist for hepatitis B, necessitating long-term management.
  • Novel antiviral therapies demonstrate potential for viral hepatitis treatment.
  • Personalized dosing of pegylated interferon and ribavirin may enhance sustained virologic response rates in hepatitis C.